查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2033212

生物製藥市場規模、佔有率、趨勢和預測：按適應症、類別和地區分類，2026-2034 年

Biopharmaceutical Market Size, Share, Trends and Forecast by Indication, Class, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3個工作天內

價格

2025年全球生物製藥市場規模為3,531億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以7.90%的複合年成長率成長，到2034年達到7,146億美元。目前，北美市場佔據主導地位，預計2025年將佔45.0%的市場。推動該市場成長的因素包括慢性病和罕見病患疾病的上升、基因編輯、單株抗體和mRNA平台等技術的進步，以及公共和私人投資對研發活動的積極支持。許多國家良好的法規環境為新藥的快速核准和上市提供了獎勵。此外，開發中國家意識的提高正在擴大生物製藥的全球影響力，並進一步提升其市場佔有率。

生物製藥產業的驅動力來自科學技術的進步、不斷成長的醫療保健需求以及完善的管理體制。其中一個關鍵促進因素是慢性複雜疾病（如癌症、自體免疫疾病和罕見疾病）的日益普遍，這些疾病需要新型的標靶治療方法。對個人化醫療的日益重視以及開發針對個人基因譜客製化治療方法的潛力，也推動了生物製藥研發的發展。此外，基因編輯、mRNA技術和細胞療法等生物技術創新，正在實現以往無法企及的突破性進展。世界各國政府和醫療機構也透過資金支持、稅收優惠和加速核准流程，大力投資生物製藥創新。全球老化是另一個主要促進因素，它增加了對更有效率、更持久治療方法的需求。這些因素共同創造了生物製藥產業強勁、競爭激烈且創新驅動的環境，從而推動了市場成長。

美國憑藉其無與倫比的創新、投資和基礎設施優勢，成為領先的市場驅動力。許多世界級的生物技術和製藥公司匯聚於此，在研發領域，尤其是在基因治療、mRNA技術和免疫腫瘤學等領域，透過持續創新發揮主導作用。眾多知名研究中心、強大的創業投資支持以及清晰的法規環境，加速了科學進步。美國食品藥物管理局（FDA）在促進創新方面發揮著至關重要的作用，它提供快速核准途徑，同時確保安全性。此外，生物技術新創公司、學術機構和大型製藥企業之間的合作，促進了創新治療方法的大規模商業化。不斷上漲的醫療保健成本和對早期藥物應用的需求，使美國成為未來生物製藥領域的主要創新者，在定價策略、臨床試驗設計和國際監管方向方面引領潮流。

生物製藥市場趨勢

慢性病盛行率增加

全球慢性疾病（如癌症、糖尿病、心血管疾病和自體免疫疾病）的日益增多是生物製藥市場的重要驅動力。由於慢性疾病需要長期治療，且通常依賴生物製藥進行管理和治療，因此對這些產品的需求不斷成長。例如，癌症已成為生物製藥的關鍵領域，這得益於標靶治療的開發，與傳統化療相比，標靶療法能夠提供更有效、更個人化的治療方案。根據世界衛生組織（WHO）統計，癌症是全球第二大死因，2022年全球新增癌症病例約2000萬例，死亡人數達970萬人。全球癌症發生率的上升要求持續進行生物製藥（如單株抗體和癌症疫苗）的研究、開發和推廣，這些藥物通常被認為比傳統治療方法更有效且副作用更少。這種需求促使大型製藥企業加大研發投入，並增加了公共和私人資金，用於應對這些慢性疾病。

生物製藥領域取得顯著進展

生物製藥領域的進步對市場的演進和成長至關重要。這些進步包括基因工程、高通量篩檢技術和次世代定序。這些技術正在提升研究人員在分子層面上理解疾病的能力，並開發出更有效、更安全的標靶疾病藥物，進一步塑造了生物製藥市場的光明前景。根據IMARC Group預測，全球基因組學市場規模預計在2024年達到384億美元，到2033年達到1,133億美元，2025年至2033年的複合年成長率（CAGR）為12.77%。這一成長表明基因組學在藥物發現和個人化醫療中發揮關鍵作用，而這兩者對於生物製藥的發展至關重要。生物技術工具的改進正在加速藥物發現進程，提高藥物研發的成功率，進一步吸引投資和研究進入該領域。

政府支持和不斷上漲的醫療保健成本

根據對生物製藥市場的預測，政府措施和醫療保健支出是推動市場發展的關鍵因素。世界各國政府都在增加醫療保健預算，其中包括對生物製藥研發的投入。例如，根據美國醫療保險和醫療服務中心（CMS）的數據顯示，2023年美國醫療保健支出增加了7.5%，達到4.9兆美元。整體而言，醫療保健支出占美國GDP的17.6%。已開發國家尤其如此，這些國家將持續創新視為策略重點，以維持在全球醫療保健市場的競爭優勢。例如，根據《印度斯坦時報》報道，印度每年在生物醫學研究的支出約為14億美元。這項對醫學研究的巨額投資反映了政府對生物製藥產業的支持，為加速研發和先進治療方法的推出提供了必要的資金。這種政府支持增強了生物製藥公司的研發能力，並促進了新藥的快速商業化。這將使這些創新成果進入市場，並惠及有需要的患者，從而為生物製藥市場創造光明前景。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球生物製藥市場

  • 市場趨勢與預測
  • 新冠疫情的影響
  • 市場：按地區
  • 市場：按適應症分類
  • 市場：按類別
  • 競爭格局
    • 生物製藥業的領先公司
    • 主要生物製藥公司
  • 價值鏈分析
  • 波特五力分析

第6章 北美洲

  • 美國
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）
  • 加拿大
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）

第7章 拉丁美洲

  • 墨西哥
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）
  • 巴西
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）
  • 阿根廷
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）

第8章 歐洲

  • 德國
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）
  • 法國
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）
  • 義大利
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）
  • 西班牙
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）
  • 英國
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）
  • 俄羅斯
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）
  • 土耳其
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）

第9章 亞太地區

  • 日本
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）
  • 中國
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）
  • 澳洲
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）
  • 韓國
    • 市場表現（2020-2025）
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）
  • 印度
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）
  • 印尼
    • 市場表現（2020-2025）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白
    • 大公司
    • 市場預測（2026-2034）

第10章 SWOT 分析

第11章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • AbbVie Inc.
    • Amgen Inc
    • Biogen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112026A722

The global biopharmaceutical market size was valued at USD 353.1 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 714.6 Billion by 2034, exhibiting a CAGR of 7.90% during 2026-2034. North America currently dominates the market, holding a significant market share of 45.0% in 2025. The market is propelled by the growing incidence of chronic and rare diseases, advances in technologies like gene editing, monoclonal antibodies, and mRNA platforms and committed investment from private and public sources fueling research and development activities. Positive regulatory climates in most nations providing incentives for quick approvals and access to the market for new drugs, along with increasing healthcare infrastructure and awareness in developing economies to extend the sales reach of biopharmaceutical products globally, are further increasing the biopharmaceutical market share.

The biopharmaceutical industry is being propelled by the confluence of scientific developments, growing healthcare demands, and facilitative regulatory regimes. A significant driver among them is the growth in incidence rates of chronic and complex conditions, including cancer, autoimmune diseases, and orphan diseases, that necessitate new and targeted treatments. The increasing emphasis on personalized medicine and the potential to create therapies targeted to individual genetic profiles are also driving biopharmaceutical R&D. Moreover, innovation in biotechnology, such as gene editing, mRNA technologies, and cell therapy, is driving breakthroughs which were not possible before. Governments and healthcare organizations globally are also heavily investing in biopharmaceutical innovation through funding, tax credits, and expedited approval processes. The aging population worldwide is another major driver, leading to increased need for more efficient and long-term treatments. These forces together are creating a strong and competitive environment in the biopharmaceutical sector, with innovation being at the center, which helps in fueling the biopharmaceutical market growth.

The United States stands out as a key market disruptor, driven by its unparalleled blend of innovation, investment, and infrastructure. It hosts numerous of the world's top biotech and pharmaceutical firms, and the US leads through ongoing innovation in research and development, especially in fields such as gene therapy, mRNA technologies, and immuno-oncology. The availability of renowned research centers, strong venture capital backing, and a well-defined regulatory environment allows for swift scientific advancement. The US Food and Drug Administration (FDA) is significant in providing fast-track approval options and encouraging innovation while not jeopardizing safety. Additionally, collaboration among biotech start-ups, academia, and international pharma majors facilitates large-scale commercialization of innovative treatments. With elevated healthcare expenditures and early uptake of new medicines, the US drives pricing strategies, trial designs, and international regulatory directions, making US the leading disruptor of the future of biopharmaceuticals.

BIOPHARMACEUTICAL MARKET TRENDS

Increased Prevalence of Chronic Diseases

The global rise in chronic diseases such as cancer, diabetes, cardiovascular diseases, and autoimmune disorders is a significant driver of the biopharmaceutical market. Chronic diseases require prolonged treatment and often rely on biopharmaceuticals for management and therapy, driving demand for these products. For instance, cancer has become a critical area for biopharmaceuticals with the development of targeted therapies that provide more effective and personalized treatment options compared to traditional chemotherapeutics. As reported by the World Health Organization, cancer ranks as the second highest cause of death worldwide, with around 20 Million new cancer cases and 9.7 Million fatalities in 2022. The rising worldwide cancer rates require continuous advancement and market introduction of biopharmaceuticals, including monoclonal antibodies and cancer vaccines, which typically prove to be more effective and have reduced side effects compared to traditional therapies. This need results in significant investments in research and development by leading pharmaceutical firms and an increase in both public and private funding focused on addressing these chronic illnesses.

Significant Advancements in Biopharmaceutical

Biopharmaceutical advancements are pivotal in the evolution and growth of the market. These advancements include genetic engineering, high-throughput screening technologies, and next-generation sequencing, among others. These technologies enhance the ability of researchers to understand diseases at a molecular level and to develop drugs that can target these diseases more effectively and safely, further shaping a positive biopharmaceutical market outlook. According to the IMARC Group, the global genomics market reached USD 38.4 Billion in 2024 and is expected to reach USD 113.3 Billion by 2033, exhibiting a growth rate (CAGR) of 12.77% during 2025-2033. This growth is indicative of the critical role genomics plays in drug discovery and personalized medicine, both of which are essential to the development of biopharmaceuticals. Improved biotechnological tools speed up the drug discovery process and also increase the success rate of the drugs developed, thereby attracting more investments and research into this sector.

Rising Government Support and Healthcare Expenditure

Government initiatives and healthcare spending are crucial in propelling the market according to the biopharmaceutical market forecast. Many governments worldwide are increasing their healthcare budgets, which includes funding for the research and development of biopharmaceuticals. For instance, expenditure on healthcare in the United States increased by 7.5% in 2023, reaching USD 4.9 Trillion, according to the Centers for Medicare and Medicaid Services (CMS). Overall, healthcare expenditure accounted for 17.6% of the GDP of the country. This is particularly evident in developed countries, where there is a strategic focus on sustaining innovation to maintain a competitive edge in the global healthcare market. For instance, India spends almost $ 1.4 billion on biomedical research, according to the HINDUSTAN TIMES. This substantial investment in health research reflects the support of the government for the biopharmaceutical industry, providing the necessary financial resources to fuel research, development, and the adoption of advanced therapies. Such government backing enhances the development capabilities of biopharmaceutical firms and helps in the faster commercialization of new drugs, ensuring that these innovations reach the market and become accessible to patients in need, thus creating a positive biopharmaceutical market outlook.

BIOPHARMACEUTICAL INDUSTRY SEGMENTATION:

Analysis by Indication:

  • Autoimmune Diseases
  • Oncology
  • Metabolic Disorders
  • Others

Autoimmune diseases stand as the largest component in 2025. Autoimmune diseases represent the largest segment in market breakup by indication within the biopharmaceutical sector primarily due to the high prevalence and chronic nature of these conditions, coupled with a significant unmet need for effective and sustainable treatments. Autoimmune diseases, which include conditions such as rheumatoid arthritis, multiple sclerosis, and lupus, affect millions globally, necessitating long-term, often lifelong management. The complexity of these diseases, characterized by the immune system mistakenly attacking the tissues of their own body, demands therapies that are highly specific and capable of modulating immune responses without severe side effects. Biopharmaceuticals, particularly biologics such as monoclonal antibodies and fusion proteins, have been revolutionary in this field. They offer targeted therapies that specifically address underlying immune dysfunctions, leading to better disease management and improved quality of life for patients.

Analysis by Class:

  • Recombinant Proteins
  • Monoclonal Antibodies
  • Purified Proteins

Monoclonal antibodies lead the market with 47.6% of market share in 2025. Monoclonal antibodies dominate the biopharmaceutical market as the largest segment in market breakdown by class due to their highly targeted therapeutic capabilities and broad applicability across various diseases. These antibodies are engineered to bind to specific antigens present on the surface of cells or pathogens, allowing for precise targeting of diseases such as cancer, autoimmune disorders, and infectious diseases. Their ability to be tailored for specific targets enhances their efficacy and minimizes off-target effects, which contributes to their substantial market share. The growing prevalence of chronic diseases and the increasing demand for personalized medicine have further amplified the reliance on monoclonal antibodies, thereby creating a positive biopharmaceutical industry overview.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Turkey
  • Asia Pacific
    • Japan
    • China
    • Australia
    • South Korea
    • India
    • Indonesia

In 2025, North America accounted for the largest market share of 45.0%. North America is the largest segment in the global biopharmaceutical market primarily due to its well-established healthcare infrastructure, significant research and development investments, and a robust regulatory framework. The United States is home to numerous leading biopharmaceutical companies and research institutions that drive innovation in drug development and biopharmaceutical. The region benefits from substantial public and private funding, which supports extensive R&D activities and the commercialization of advanced therapeutics. Additionally, the high healthcare spending and advanced medical infrastructure of North America ensure that new biopharmaceutical products are rapidly adopted and integrated into clinical practice.

KEY REGIONAL TAKEAWAYS:

UNITED STATES BIOPHARMACEUTICAL MARKET ANALYSIS

In 2025, the United States accounted for over 91.20% of the biopharmaceutical market in North America. The United States biopharmaceutical market is primarily driven by advancements in biotechnology, particularly in gene and cell therapies, which have opened new avenues for treating previously untreatable conditions, such as certain cancers and genetic disorders. Technologies such as CRISPR-Cas9 and CAR-T cell therapies are at the forefront of this transformation, enabling more targeted and personalized treatments. Additionally, the success of mRNA technology is increasing investment into mRNA-based therapeutics, expanding their application beyond vaccines to include treatments for cancer and rare diseases. The increasing geriatric population in the United States is also contributing to the heightened demand for treatments targeting age-related diseases such as Alzheimer's, osteoporosis, and cardiovascular conditions, as well as chronic diseases such as diabetes and arthritis. According to the American Diabetes Association, 11.6% of the population in the United States suffered from diabetes in 2021, equating to 38.4 million individuals. Out of these, individuals aged 65 years and older accounted for 29.2% of the total, equating to 16.5 million seniors suffering from diabetes, both diagnosed and undiagnosed. This demographic shift is propelling the need for innovative biopharmaceutical solutions to manage long-term health challenges. Other than this, the United States maintains a robust healthcare infrastructure and a favorable regulatory environment, which incentivize the development of treatments for rare diseases.

ASIA PACIFIC BIOPHARMACEUTICAL MARKET ANALYSIS

The Asia Pacific biopharmaceutical market is expanding due to a rapidly growing population, an expanding middle class, and increasing healthcare awareness among consumers. Rising prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders has heightened the demand for advanced and targeted therapies. Technological advancements in biotechnology and bioscience research, combined with a growing pool of skilled professionals, are further contributing to innovation and product development. Moreover, favorable demographic trends, such as an increasing geriatric population, are intensifying the need for biologics and specialty treatments. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), 670 million people in the Asia-Pacific area were 60 years of age or older in 2022. By 2050, this figure is anticipated to increase to 1.3 billion. In addition, the growing acceptance of biologics over conventional medications and the increasing affordability of healthcare are driving industry growth.

EUROPE BIOPHARMACEUTICAL MARKET ANALYSIS

The Europe biopharmaceutical market is experiencing robust growth, fueled by the increasing prevalence of chronic and rare diseases, which is driving the demand for innovative, high-efficacy treatments. According to Eurostat, in 2023, more than 35.0% of the population in the European Union reported suffering from a chronic illness. Rising health awareness among the population has led to earlier diagnosis and increased demand for precision medicine, which relies heavily on biologics and targeted therapies. The growing adoption of digital health technologies, such as AI-driven drug discovery platforms, wearable diagnostics, and real-world data integration, has also significantly expedited research timelines and optimized clinical development. Additionally, strategic collaborations between academic research institutions and pharmaceutical developers have enhanced innovation pipelines, leading to a wider array of biologics reaching clinical trials. Moreover, the expansion of biosimilars, particularly in cost-sensitive markets within Europe, is increasing patient access to biologic treatments while maintaining market growth. The development of advanced manufacturing platforms, such as continuous bioprocessing and single-use technologies, has also improved production efficiency and scalability. Other than this, the diverse patient pool and structured clinical research infrastructure in Europe make it a strategic location for clinical trials, which further supports product development and commercialization. Increasing consumer preference for personalized and minimally invasive treatments is also driving demand for advanced biopharmaceuticals over traditional small-molecule drugs.

LATIN AMERICA BIOPHARMACEUTICAL MARKET ANALYSIS

The Latin America biopharmaceutical market is significantly influenced by the region's increasing integration into global supply chains, which enhances access to raw materials, technologies, and expertise essential for biologics manufacturing. Improvements in cold chain logistics and storage capabilities are also making it easier to distribute temperature-sensitive biopharmaceutical products across remote and underserved areas, expanding market reach and patient access. For instance, the cold chain logistics market in Brazil is expected to reach USD 5.3 Billion by 2032, growing at a CAGR of 9.23% during 2024-2032, as reported by the IMARC Group. Additionally, the region's expanding healthcare infrastructure and investments in research and development (R&D) are fostering innovation and improving access to biopharmaceutical products. Consumer preferences are also shifting toward higher-quality and more effective treatments, encouraging the adoption of innovative biopharmaceuticals over conventional medicines.

COMPETITIVE LANDSCAPE:

Major biopharmaceutical companies are driving growth through a variety of strategic efforts, including substantial investments in research and development (R&D), strategic partnerships, and technological advancements. Major biopharmaceutical companies such as Pfizer, Roche, and Novartis are dedicating significant resources to developing innovative therapies and expanding their product portfolios. They are also forming strategic alliances with biopharmaceutical firms, research institutions, and technology companies to accelerate drug discovery and development processes. For instance, partnerships with technology firms are enhancing capabilities in artificial intelligence and data analytics, which streamline drug discovery and improve precision medicine. According to the biopharmaceutical market forecast, these companies are also investing in cutting-edge technologies such as gene and cell therapies to address unmet medical needs and tap into emerging markets.

The report provides a comprehensive analysis of the competitive landscape in the biopharmaceutical market with detailed profiles of all major companies, including:

  • Amgen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • AbbVie Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Merck & Co. Inc.
  • Novo Nordisk A/S
  • Biogen Inc.

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

5 Global Biopharmaceutical Market

  • 5.1 Market Performance and Forecast
    • 5.1.1 Current Performance (2020-2025)
    • 5.1.2 Market Forecast (2026-2034)
  • 5.2 Impact of COVID-19
  • 5.3 Market by Region
    • 5.3.1 Current Performance (2020-2025)
    • 5.3.2 Market Forecast (2026-2034)
  • 5.4 Market by Indication
    • 5.4.1 Autoimmune Diseases
    • 5.4.2 Oncology
    • 5.4.3 Metabolic Disorders
    • 5.4.4 Others
  • 5.5 Market by Class
    • 5.5.1 Recombinant Proteins
      • 5.5.1.1 Current Performance (2020-2025)
      • 5.5.1.2 Market Forecast (2026-2034)
    • 5.5.2 Monoclonal Antibodies
      • 5.5.2.1 Current Performance (2020-2025)
      • 5.5.2.2 Market Forecast (2026-2034)
    • 5.5.3 Purified Proteins
      • 5.5.3.1 Current Performance (2020-2025)
      • 5.5.3.2 Market Forecast (2026-2034)
  • 5.6 Competitive Landscape
    • 5.6.1 Top Biopharmaceutical Players
    • 5.6.2 Top Biopharmaceutical Drugs
  • 5.7 Value Chain Analysis
  • 5.8 Porter's Five Forces Analysis
    • 5.8.1 Overview
    • 5.8.2 Bargaining Power of Buyers
    • 5.8.3 Bargaining Power of Suppliers
    • 5.8.4 Degree of Rivalry
    • 5.8.5 Threat of New Entrants
    • 5.8.6 Threat of Substitutes

6 North America

  • 6.1 United States
    • 6.1.1 Market Performance (2020-2025)
    • 6.1.2 Market by Class
      • 6.1.2.1 Recombinant Proteins
      • 6.1.2.2 Monoclonal Antibodies
      • 6.1.2.3 Purified Proteins
    • 6.1.3 Top Players
    • 6.1.4 Market Forecast (2026-2034)
  • 6.2 Canada
    • 6.2.1 Market Performance (2020-2025)
    • 6.2.2 Market by Class
      • 6.2.2.1 Recombinant Proteins
      • 6.2.2.2 Monoclonal Antibodies
      • 6.2.2.3 Purified Proteins
    • 6.2.3 Top Players
    • 6.2.4 Market Forecast (2026-2034)

7 Latin America

  • 7.1 Mexico
    • 7.1.1 Market Performance (2020-2025)
    • 7.1.2 Market by Class
      • 7.1.2.1 Recombinant Proteins
      • 7.1.2.2 Monoclonal Antibodies
      • 7.1.2.3 Purified Proteins
    • 7.1.3 Top Players
    • 7.1.4 Market Forecast (2026-2034)
  • 7.2 Brazil
    • 7.2.1 Market Performance (2020-2025)
    • 7.2.2 Market by Class
      • 7.2.2.1 Recombinant Proteins
      • 7.2.2.2 Monoclonal Antibodies
      • 7.2.2.3 Purified Proteins
    • 7.2.3 Top Players
    • 7.2.4 Market Forecast (2026-2034)
  • 7.3 Argentina
    • 7.3.1 Market Performance (2020-2025)
    • 7.3.2 Market by Class
      • 7.3.2.1 Recombinant Proteins
      • 7.3.2.2 Monoclonal Antibodies
      • 7.3.2.3 Purified Proteins
    • 7.3.3 Top Players
    • 7.3.4 Market Forecast (2026-2034)

8 Europe

  • 8.1 Germany
    • 8.1.1 Market Performance (2020-2025)
    • 8.1.2 Market by Class
      • 8.1.2.1 Recombinant Proteins
      • 8.1.2.2 Monoclonal Antibodies
      • 8.1.2.3 Purified Proteins
    • 8.1.3 Top Players
    • 8.1.4 Market Forecast (2026-2034)
  • 8.2 France
    • 8.2.1 Market Performance (2020-2025)
    • 8.2.2 Market by Class
      • 8.2.2.1 Recombinant Proteins
      • 8.2.2.2 Monoclonal Antibodies
      • 8.2.2.3 Purified Proteins
    • 8.2.3 Top Players
    • 8.2.4 Market Forecast (2026-2034)
  • 8.3 Italy
    • 8.3.1 Market Performance (2020-2025)
    • 8.3.2 Market by Class
      • 8.3.2.1 Recombinant Proteins
      • 8.3.2.2 Monoclonal Antibodies
      • 8.3.2.3 Purified Proteins
    • 8.3.3 Top Players
    • 8.3.4 Market Forecast (2026-2034)
  • 8.4 Spain
    • 8.4.1 Market Performance (2020-2025)
    • 8.4.2 Market by Class
      • 8.4.2.1 Recombinant Proteins
      • 8.4.2.2 Monoclonal Antibodies
      • 8.4.2.3 Purified Proteins
    • 8.4.3 Top Players
    • 8.4.4 Market Forecast (2026-2034)
  • 8.5 United Kingdom
    • 8.5.1 Market Performance (2020-2025)
    • 8.5.2 Market by Class
      • 8.5.2.1 Recombinant Proteins
      • 8.5.2.2 Monoclonal Antibodies
      • 8.5.2.3 Purified Proteins
    • 8.5.3 Top Players
    • 8.5.4 Market Forecast (2026-2034)
  • 8.6 Russia
    • 8.6.1 Market Performance (2020-2025)
    • 8.6.2 Market by Class
      • 8.6.2.1 Recombinant Proteins
      • 8.6.2.2 Monoclonal Antibodies
      • 8.6.2.3 Purified Proteins
    • 8.6.3 Top Players
    • 8.6.4 Market Forecast (2026-2034)
  • 8.7 Turkey
    • 8.7.1 Market Performance (2020-2025)
    • 8.7.2 Market by Class
      • 8.7.2.1 Recombinant Proteins
      • 8.7.2.2 Monoclonal Antibodies
      • 8.7.2.3 Purified Proteins
    • 8.7.3 Top Players
    • 8.7.4 Market Forecast (2026-2034)

9 Asia Pacific

  • 9.1 Japan
    • 9.1.1 Market Performance (2020-2025)
    • 9.1.2 Market by Class
      • 9.1.2.1 Recombinant Proteins
      • 9.1.2.2 Monoclonal Antibodies
      • 9.1.2.3 Purified Proteins
    • 9.1.3 Top Players
    • 9.1.4 Market Forecast (2026-2034)
  • 9.2 China
    • 9.2.1 Market Performance (2020-2025)
    • 9.2.2 Market by Class
      • 9.2.2.1 Recombinant Proteins
      • 9.2.2.2 Monoclonal Antibodies
      • 9.2.2.3 Purified Proteins
    • 9.2.3 Top Players
    • 9.2.4 Market Forecast (2026-2034)
  • 9.3 Australia
    • 9.3.1 Market Performance (2020-2025)
    • 9.3.2 Market by Class
      • 9.3.2.1 Recombinant Proteins
      • 9.3.2.2 Monoclonal Antibodies
      • 9.3.2.3 Purified Proteins
    • 9.3.3 Top Players
    • 9.3.4 Market Forecast (2026-2034)
  • 9.4 South Korea
    • 9.4.1 Market Performance (2020-2025)
      • 9.4.1.1 Recombinant Proteins
      • 9.4.1.2 Monoclonal Antibodies
      • 9.4.1.3 Purified Proteins
    • 9.4.2 Top Players
    • 9.4.3 Market Forecast (2026-2034)
  • 9.5 India
    • 9.5.1 Market Performance (2020-2025)
    • 9.5.2 Market by Class
      • 9.5.2.1 Recombinant Proteins
      • 9.5.2.2 Monoclonal Antibodies
      • 9.5.2.3 Purified Proteins
    • 9.5.3 Top Players
    • 9.5.4 Market Forecast (2026-2034)
  • 9.6 Indonesia
    • 9.6.1 Market Performance (2020-2025)
    • 9.6.2 Market by Class
      • 9.6.2.1 Recombinant Proteins
      • 9.6.2.2 Monoclonal Antibodies
      • 9.6.2.3 Purified Proteins
    • 9.6.3 Top Players
    • 9.6.4 Market Forecast (2026-2034)

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Competitive Landscape

  • 11.1 Market Structure
  • 11.2 Key Players
  • 11.3 Profiles of Key Players
    • 11.3.1 AbbVie Inc.
    • 11.3.2 Amgen Inc
    • 11.3.3 Biogen Inc.
    • 11.3.4 Eli Lilly and Company
    • 11.3.5 F. Hoffmann-La Roche AG
    • 11.3.6 Johnson & Johnson
    • 11.3.7 Merck & Co. Inc.
    • 11.3.8 Novo Nordisk A/S
    • 11.3.9 Pfizer Inc.
    • 11.3.10 Sanofi S.A

List of Figures

  • Figure 1: Global: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 2: Complexity of Biopharmaceuticals
  • Figure 3: Sources of Biopharmaceuticals
  • Figure 4: Global: Biopharmaceutical Market: Value Trends (in Billion USD), 2020-2025
  • Figure 5: Global: Biopharmaceutical Market Forecast: Value Trends (in Billion USD), 2026-2034
  • Figure 6: Global: Biopharmaceutical Market: Sales Share by Country (in %), 2025
  • Figure 7: Global: Biopharmaceutical Market Forecast: Sales Share by Country (in %), 2034
  • Figure 8: Global: Biopharmaceutical Market: Sales Share by Indication (in %), 2025
  • Figure 9: Global: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 10: Global: Biopharmaceutical Market Forecast: Sales by Class (in Million USD), 2026-2034
  • Figure 11: Global: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 12: Global: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 13: Global: Recombinant Proteins Market Forecast (in Million USD), 2026-2034
  • Figure 14: Global: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 15: Global: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 16: Global: Monoclonal Antibodies Market Forecast (in Million USD), 2026-2034
  • Figure 17: Global: Purified Proteins Market (in Million USD), 2020-2025
  • Figure 18: Global: Purified Proteins Market: Sales Share by Class (in %), 2025
  • Figure 19: Global: Purified Proteins Market Forecast (in Million USD), 2026-2034
  • Figure 20: Global: Biopharmaceutical Market: Sales Share of Top Biopharmaceuticals (in %)
  • Figure 21: Global: Biopharmaceutical Industry: Value Chain Analysis
  • Figure 22: Global: Biopharmaceutical Industry: Porter's Five Forces Analysis
  • Figure 23: United States: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 24: United States: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 25: United States: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 26: United States: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 27: United States: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 28: United States: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 29: United States: Purified Proteins Market (in Million USD), 2020-2025
  • Figure 30: United States: Purified Proteins Market: Sales Share by Class (in %), 2025
  • Figure 31: United States: Biopharmaceutical Market: Sales Share of Top Players (in %), 2025
  • Figure 32: United States: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 33: United States: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 34: Canada: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 35: Canada: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 36: Canada: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 37: Canada: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 38: Canada: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 39: Canada: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 40: Canada: Biopharmaceutical Market: Sales Share of Top Players (in %), 2025
  • Figure 41: Canada: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 42: Canada: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 43: Mexico: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 44: Mexico: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 45: Mexico: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 46: Mexico: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 47: Mexico: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 48: Mexico: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 49: Mexico: Purified Proteins Market (in '000 USD), 2020-2025
  • Figure 50: Mexico: Biopharmaceutical Market: Sales Share of Top Players (in %), 2025
  • Figure 51: Mexico: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 52: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 53: Brazil: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 54: Brazil: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 55: Brazil: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 56: Brazil: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 57: Brazil: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 58: Brazil: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 59: Brazil: Purified Proteins Market (in Million USD), 2020-2025
  • Figure 60: Brazil: Biopharmaceutical Market: Sales Share of Top Players (in %), 2025
  • Figure 61: Brazil: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 62: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 63: Argentina: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 64: Argentina: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 65: Argentina: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 66: Argentina: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 67: Argentina: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 68: Argentina: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 69: Argentina: Purified Proteins Market (in Million USD), 2020-2025
  • Figure 70: Argentina: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 71: Argentina: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 72: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 73: Germany: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 74: Germany: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 75: Germany: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 76: Germany: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 77: Germany: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 78: Germany: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 79: Germany: Purified Proteins Market (in Million USD), 2020-2025
  • Figure 80: Germany: Purified Proteins Market: Sales Share by Class (in %), 2025
  • Figure 81: Germany: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 82: Germany: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 83: Germany: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 84: France: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 85: France: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 86: France: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 87: France: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 88: France: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 89: France: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 90: France: Purified Proteins Market (in Million USD), 2020-2025
  • Figure 91: France: Biopharmaceutical Market: Sales Share of Top Players (in %), 2025
  • Figure 92: France: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 93: France: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 94: Italy: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 95: Italy: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 96: Italy: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 97: Italy: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 98: Italy: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 99: Italy: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 100: Italy: Purified Proteins Market (in Million USD), 2020-2025
  • Figure 101: Italy: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 102: Italy: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 103: Italy: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 104: Spain: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 105: Spain: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 106: Spain: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 107: Spain: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 108: Spain: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 109: Spain: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 110: Spain: Purified Proteins Market (in Million USD), 2020-2025
  • Figure 111: Spain: Purified Proteins Market: Sales Share by Class (in %), 2025
  • Figure 112: Spain: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 113: Spain: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 114: Spain: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 115: UK: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 116: UK: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 117: UK: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 118: UK: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 119: UK: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 120: UK: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 121: UK: Purified Proteins Market (in Million USD), 2020-2025
  • Figure 122: UK: Purified Proteins Market: Sales Share by Class (in %), 2025
  • Figure 123: UK: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 124: UK: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 125: UK: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 126: Russia: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 127: Russia: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 128: Russia: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 129: Russia: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 130: Russia: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 131: Russia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 132: Russia: Purified Proteins Market: (in Million USD), 2020-2025
  • Figure 133: Russia: Purified Proteins Market: Sales Share by Class (in %), 2025
  • Figure 134: Russia: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 135: Russia: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 136: Russia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 137: Turkey: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 138: Turkey: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 139: Turkey: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 140: Turkey: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 141: Turkey: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 142: Turkey: Purified Proteins Market (in Million USD), 2020-2025
  • Figure 143: Turkey: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 144: Turkey: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 145: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 146: Japan: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 147: Japan: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 148: Japan: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 149: Japan: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 150: Japan: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 151: Japan: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 152: Japan: Purified Proteins Market (in Million USD), 2020-2025
  • Figure 153: Japan: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 154: Japan: Biopharmaceutical Market Forecast: Value trend (in Million USD), 2026-2034
  • Figure 155: Japan: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 156: China: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 157: China: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 158: China: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 159: China: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 160: China: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 161: China: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 162: China: Purified Proteins Market: (in Million USD), 2020-2025
  • Figure 163: China: Purified Proteins Market: Sales Share by Class (in %), 2025
  • Figure 164: China: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 165: China: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 166: China: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 167: Australia: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 168: Australia: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 169: Australia: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 170: Australia: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 171: Australia: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 172: Australia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 173: Australia: Purified Proteins Market (in Million USD), 2020-2025
  • Figure 174: Australia: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 175: Australia: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 176: Australia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 177: South Korea: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 178: South Korea: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 179: South Korea: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 180: South Korea: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 181: South Korea: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 182: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2025
  • Figure 183: South Korea: Purified Proteins Market (in Million USD), 2020-2025
  • Figure 184: South Korea: Purified Proteins Market: Sales Share by Class (in %), 2025
  • Figure 185: South Korea: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 186: South Korea: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 187: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 188: India: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 189: India: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 190: India: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 191: India: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 192: India: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 193: India: Purified Proteins Market (in Million USD), 2020-2025
  • Figure 194: India: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 195: India: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 196: India: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 197: Indonesia: Biopharmaceutical Market (in Million USD), 2020-2025
  • Figure 198: Indonesia: Biopharmaceutical Market: Sales by Class (in Million USD), 2020-2025
  • Figure 199: Indonesia: Recombinant Proteins Market (in Million USD), 2020-2025
  • Figure 200: Indonesia: Recombinant Proteins Market: Sales Share by Class (in %), 2025
  • Figure 201: Indonesia: Monoclonal Antibodies Market (in Million USD), 2020-2025
  • Figure 202: Indonesia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2025
  • Figure 203: Indonesia: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 204: Indonesia: Biopharmaceutical Market Forecast (in Million USD), 2026-2034
  • Figure 205: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2034
  • Figure 206: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2001 & 2022
  • Figure 207: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products
  • Figure 208: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used
  • Figure 209: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %)
  • Figure 210: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs (in USD)
  • Figure 211: Emerging Biopharmaceutical Market Forecast (in Million USD), 2025 & 2034
  • Figure 212: Developed Biopharmaceutical Market Forecast (in Million USD), 2025 & 2034
  • Figure 213: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in Numbers), 2002-2022
  • Figure 214: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs (in Million USD)
  • Figure 215: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months)

List of Tables

  • Table 1: Global: Biopharmaceutical Market: Definition & Segmentation
  • Table 2: Global: Biopharmaceutical Market: SWOT Analysis
  • Table 3: Global: Biopharmaceutical Market Forecast: Sales by Region (in Million USD), 2025 & 2034
  • Table 4: Differences Between Small Molecule Drugs & Biopharmaceuticals
  • Table 5: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs
  • Table 6: Global: Biopharmaceutical Market: Sales by Country (in Million USD), 2020-2025
  • Table 7: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million USD), 2026-2034
  • Table 8: Global: Biopharmaceutical Market: Sales by Indication (in Billion USD), 2025
  • Table 9: Mode of Administration of Popular Biotech Drugs